SynBio(CP00070.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
SynBio
CP00070.US
News
View More

Beam Therapeutics: Undervalued Base-Editing Leader with De-Risked BEAM-302 Driving $46 Price Target and Overweight/Buy Rating

J.P. Morgan analyst Brian Cheng has maintained a Buy rating on Beam Therapeutics, setting a price target of $46. He cites the company's base-editing technology and the promising BEAM-302 program for alpha-1 antitrypsin deficiency as key factors. The recent regulatory alignment for accelerated approval reduces development risks. Cheng's analysis indicates that the current share price does not reflect Beam's potential, justifying an Overweight/Buy recommendation. Bernstein also supports this with a Buy rating and a $41 price target.

Tip Ranks·
US
PBE
+1.86%
US
BEAM
+1.13%
US
IBBQ
+2.21%
Tip Ranks·
US
PBE
+1.86%
US
BEAM
+1.13%
US
IBBQ
+2.21%

Beam Therapeutics Chief Legal Officer Christine Bellon Reports Disposal of Common Shares

Christine Bellon, Chief Legal Officer of Beam Therapeutics Inc., has reported the disposal of common shares of the company. The full filing is available through the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

Reuters·
US
BIB
+4.50%
US
BBH
+2.82%
US
FBT
+3.45%
Reuters·
US
BIB
+4.50%
US
BBH
+2.82%
US
FBT
+3.45%

Cathie Wood's Ark Invest teases 'ARKmojis' for 2026 strategic picks, with 3 top ideas: AI Agents, Genomics & more.

Cathie Wood's Ark Invest has introduced 'ARKmojis' to represent their strategic picks for 2026, focusing on AI agents and genomics. They shared six ARKmojis on X, inviting followers to interpret them. The first image, related to AI agents, received votes for options like AI Agent Takeover and AI Consumer Op System. The second image, depicting a DNA helix, hinted at genomics, with options including molecular diagnostics and aging backwards. Companies like Palantir Technologies, Tempus AI, and Crispr Therapeutics are part of their current portfolio.

Unusual Whales·
US
SBIO
+1.83%
US
XBI
+2.20%
US
IBBQ
+2.21%
Unusual Whales·
US
SBIO
+1.83%
US
XBI
+2.20%
US
IBBQ
+2.21%

Cathie Wood Buys AI Chips, Sells Tesla

Cathie Wood's ARK Invest is increasing investments in AI infrastructure and gene editing while reducing exposure to Tesla and other mature companies. Recent purchases include Advanced Micro Devices, Broadcom, and Taiwan Semiconductor Manufacturing, reflecting confidence in AI chip demand. ARK also invested in life sciences firms like Intellia Therapeutics and 10x Genomics, while selling over 86K shares of Tesla. The strategy emphasizes a shift towards next-generation technologies and automation, with a focus on robotaxis and autonomous trucking.

GuruFocus·
US
CRSP
+3.57%
US
NTLA
+7.79%
US
XBI
+2.20%
GuruFocus·
US
CRSP
+3.57%
US
NTLA
+7.79%
US
XBI
+2.20%

3 Seasonal Stocks to Buy Immediately

The Sunday Digest highlights three seasonal stocks to buy immediately, including ServiceNow Inc. (NOW), which is expected to perform well in Q4 due to increased spending by Fortune 500 companies. The article also mentions a list of top bets for 2026, featuring companies like Rocket Cos. Inc. (RKT) and Crispr Therapeutics AG (CRSP). The focus is on stocks that should be held for at least a year for maximum returns, while also acknowledging the potential for faster-moving investors to outperform through a proven trading system.

InvestorPlace·
US
CRSP
+3.57%
US
NOW
-0.16%
US
RKT
-3.02%
InvestorPlace·
US
CRSP
+3.57%
US
NOW
-0.16%
US
RKT
-3.02%
Posts
View More

The recent biotech stock market is really a tale of two extremes. CRSP and NTLA in hand are still struggling, chasing the dream of gene editing but completely missing the big surge of MLTX and ELVN, w...

$Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals Inc.（RXRX）Weekly Report (2025.11.22-11.29) The extent of your achievements can largely be seen from how much pain you can endure...

© 2026 Longbridge｜Disclaimer